tmz ppt
TRANSCRIPT
![Page 1: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/1.jpg)
TEMOZOLOMIDE
DR SAILENDRADEPT. OF RADIOTHERAPYMAULANA AZAD NEDICAL COLLEGE
![Page 2: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/2.jpg)
ADJUVANT TREATMENT RECOMMENDATION FOR GBM
• Irradiate the tumor (everything within) 3 cm margin around tumor i.e (GTV + 3cm margin), keeping in mind the CNS organs at risk .
• Treatment in Conventional schedule-60 Gy/ 30# , 2 Gy daily over 6 wks
• Radiation therapy along with TMZ is recommended in newly diagnosed GBM .
![Page 3: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/3.jpg)
![Page 4: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/4.jpg)
TEMOZOLOMIDE• Alkylating agent• Temodar (U.S), Temodal (international).• Scheringe
• MTIC(3-methyl-triazene-1yl-imadazole-4-carboxamide)
![Page 5: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/5.jpg)
MECHANISM OF ACTION• Imidazotetrazine analog that is structurally and
functionally similar to dacarbazine.• Cell cycle–nonspecific agent.• Metabolic activation to the reactive compound
MTIC is required for antitumor activity.• precise mechanism of cytotoxicity is unclear• methylates guanine residues in DNA and inhibits
DNA, RNA, and protein synthesis.
![Page 6: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/6.jpg)
• Stable at acidic ph(<5) and labile at ph>7.• Prodrug,rapid hydrolysis at physiological pH
active metabolite MTIC(3-methyl-triazene-1yl-imadazole-4-carboxamide).
• MTIC: active metabolite of dacarbazine.
![Page 7: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/7.jpg)
MECHANISM OF RESISTANCE
• Increased activity of DNA repair enzymes such as O6-methylguanineDNAmethyletransferase.
![Page 8: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/8.jpg)
• 40%–50% of the parent drug is excreted in urine within 6 hours of administration, and tubular secretion is the predominant mechanism of renal excretion.
• Widely distributed in body tissues.• Rapidly and completely absorbed with an oral
bioavailability approaching 100%.• Maximum plasma concentrations are reached
within 1 hour
![Page 9: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/9.jpg)
DOSAGE• Temozolomide is given at 75 mg/m2 PO daily for 42
days along with radiotherapy (60 Gy in 30 fractions) for newly diagnosed GBM.
• MAINTENANCE PHASE-• started 4 weeks after completion of RT• In cycle 1 at 150 mg/m2 PO daily for five days
followed by 23 days gap.• Dose of temozolomide may be escalated to 200
mg/m2 if tolerated.• Total 6 cycles to be given.
![Page 10: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/10.jpg)
DRUG INTERACTION• Drug interactions: valporic acid -
clearance by 5%• No influence:Dexamethason Phenytoin Carbamazapine H1/H2 receptor blockers Phenobarbitone
![Page 11: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/11.jpg)
TOXICITY• Myelosuppression. Dose-limiting toxicity.
Leukopenia and thrombocytopenia are commonly observed.
• Photosensitivity.• Teratogenic.• Nausea and vomiting.
-Aggressive antiemetic therapy strongly recommended.
• Headache and fatigue.
![Page 12: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/12.jpg)
RT(N=286) RT/TMZ(N=287) P-valuesMedian age(range)yr
56.6(23.1-70.8) 55.7(19-70.5) NS
Tumor resection 70% 68% NSWHO PS: 0/ 1/ 2(%)
39/ 49/ 12 39/ 48/ 13 NS
Steroids at baseline
75% 67% P=0.041
PFS( 95% CI ) 5 mth(4.2 - 5.5) 7.2 mth (5.8 - 8.3)
P<.0001
Median survival (95% CI )
12mth (11.2-13.2)
15 mth(13.6-16.8)
P<.0001
2yr survival(95% CI )
8%(4-12%) 26%(20-32%) P<.0001
TEMOZOLOMIDE:PHASE III EORTC/NCIC TRIAL RESULTS
537 patients,85 centers Stupp et.al (June 2004)
![Page 13: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/13.jpg)
![Page 14: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/14.jpg)
![Page 15: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/15.jpg)
PFS BENEFIT
OS BENEFIT
![Page 16: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/16.jpg)
![Page 17: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/17.jpg)
On 2005 trial demonstrated that knowledge of the O 6 -methylguanine-DNA methyl transferase (MGMT), ENZYME FOR DNA
REPAIR
Conclusion :This trial showed that patients with methylated (silenced) MGMT promoter sequences had
a median survival of 21.7months versus 15.3 months for those who were not MGMT silenced, in the radiotherapy alone
MGMT is a “suicide enzyme” removes methyl groups from the O6 position of guanine, thus avoiding apoptosis & decrease the activity of TMZ .
Epigenetic silencing of the MGMT gene through promoter methylation leads to increased overall survival and better response to TMZ
![Page 18: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/18.jpg)
![Page 19: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/19.jpg)
![Page 20: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/20.jpg)
NEWER AGENTS
• CARMUSTINE WAFERS• ERLOTINIB• GEFITINIB
![Page 21: Tmz ppt](https://reader035.vdocuments.us/reader035/viewer/2022070516/587593e71a28ab901c8b76f1/html5/thumbnails/21.jpg)
THANK YOU